© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 7, 513-521,
April 3, 2002
© 2002 Oxford University Press
ARTICLE |
Osteopontin Identified as Lead Marker of Colon Cancer Progression, Using Pooled Sample Expression Profiling
Affiliations of authors: D. Agrawal (Department of Cell Biology), T. Chen, R. Irby, T. J. Yeatman (Department of Surgery), M. Szabo, D. Coppola (Department of Pathology), A. Cantor (Department of Biostatistics), Interdisciplinary Oncology, H. Lee Moffitt Cancer Center, University of South Florida, Tampa; A. F. Chambers, London Regional Cancer Centre, University of Western Ontario, Canada; J. Quackenbush, The Institute for Genomic Research, Rockville, MD.
Correspondence to: Timothy J. Yeatman, M.D., Department of Surgery, H. Lee Moffitt Cancer Center, University of South Florida, 12902 Magnolia Dr., Tampa, FL 33612 (e-mail: yeatman{at}moffitt.usf.edu).
Background: New tumor markers and markers of tumor progression are needed for improved staging and for better assessment of treatment of many cancers. Gene expression profiling techniques offer the opportunity to discover such markers. We investigated the feasibility of sample pooling strategy in combination with a novel analysis algorithm to identify markers. Methods: Total RNA from human colon tumors (n = 60) of multiple stages (adenomas; cancers with modified Astler Collier stages B, C, and D; and liver metastases) were pooled within stages and compared with pooled normal mucosal specimens (n = 10) by using oligonucleotide expression arrays. Genes that showed consistent increases or decreases in their expression through tumor progression were identified. Northern blot analysis was used to validate the findings. All statistical tests were two-sided. Results: More than 300 candidate tumor markers and more than 100 markers of tumor progression were identified. Northern analysis of 11 candidate tumor markers confirmed the gene expression changes. The gene for the secreted integrin-binding protein osteopontin was most consistently differentially expressed in conjunction with tumor progression. Its potential as a progression marker was validated (Spearman's 
= 0.903; P<.001) with northern blot analysis using RNA from an independent set of 10 normal and 43 tumor samples representing all stages. Moreover, a statistically significant correlation between osteopontin protein expression and advancing tumor stage was identified with the use of 303 additional specimens (human cancer = 185, adenomas = 67, and normal mucosal specimens = 51) (Spearman's = 0.667; P<.001). Conclusions: Sample pooling can be a powerful, cost-effective, and rapid means of identifying the most common changes in a gene expression profile. We identified osteopontin as a clinically useful marker of tumor progression by use of gene expression profiling on pooled samples.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. K. Chan, O. L. Griffith, I. T. Tai, and S. J.M. Jones Meta-analysis of Colorectal Cancer Gene Expression Profiling Studies Identifies Consistently Reported Candidate Biomarkers Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 543 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-L. Chang, L. Harkins, Y.-H. Hsieh, P. Hicks, K. Sappayatosok, S. Yodsanga, S. Swasdison, A. F. Chambers, C. A. Elmets, and K.-J. Ho Osteopontin Expression in Normal Skin and Non-melanoma Skin Tumors J. Histochem. Cytochem., January 1, 2008; 56(1): 57 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Higashiyama, T. Ito, E. Tanaka, and Y. Shimada Prognostic Significance of Osteopontin Expression in Human Gastric Carcinoma Ann. Surg. Oncol., December 1, 2007; 14(12): 3419 - 3427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shao, M.K. Washington, R. Saxena, and H. Sheng Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin Carcinogenesis, December 1, 2007; 28(12): 2476 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Pollack A Perspective on DNA Microarrays in Pathology Research and Practice Am. J. Pathol., August 1, 2007; 171(2): 375 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-Mansson The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1087 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-D. Grigoriu, A. Scherpereel, P. Devos, B. Chahine, M. Letourneux, P. Lebailly, M. Gregoire, H. Porte, M.-C. Copin, and P. Lassalle Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment Clin. Cancer Res., May 15, 2007; 13(10): 2928 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Lee, M.-J. Wang, P.-R. Sudhir, G.-D. Chen, C.-W. Chi, and J.-Y. Chen Osteopontin Promotes Integrin Activation through Outside-In and Inside-Out Mechanisms: OPN-CD44V Interaction Enhances Survival in Gastrointestinal Cancer Cells Cancer Res., March 1, 2007; 67(5): 2089 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Grade, P. Hormann, S. Becker, A. B. Hummon, D. Wangsa, S. Varma, R. Simon, T. Liersch, H. Becker, M. J. Difilippantonio, et al. Gene Expression Profiling Reveals a Massive, Aneuploidy-Dependent Transcriptional Deregulation and Distinct Differences between Lymph Node-Negative and Lymph Node-Positive Colon Carcinomas Cancer Res., January 1, 2007; 67(1): 41 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Petrik, P. W. Lavori, H. Cao, Y. Zhu, P. Wong, E. Christofferson, M. J. Kaplan, H. A. Pinto, P. Sutphin, A. C. Koong, et al. Plasma Osteopontin Is an Independent Prognostic Marker for Head and Neck Cancers J. Clin. Oncol., November 20, 2006; 24(33): 5291 - 5297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Packer, S. Pavey, A. Parker, M. Stark, P. Johansson, B. Clarke, P. Pollock, M. Ringner, and N. Hayward Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN Carcinogenesis, September 1, 2006; 27(9): 1778 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Y. Wai, Z. Mi, C. Gao, H. Guo, C. Marroquin, and P. C. Kuo Ets-1 and Runx2 Regulate Transcription of a Metastatic Gene, Osteopontin, in Murine Colorectal Cancer Cells J. Biol. Chem., July 14, 2006; 281(28): 18973 - 18982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Allan, R. George, S. A. Vantyghem, M. W. Lee, N. C. Hodgson, C. J. Engel, R. L. Holliday, D. P. Girvan, L. A. Scott, C. O. Postenka, et al. Role of the Integrin-Binding Protein Osteopontin in Lymphatic Metastasis of Breast Cancer Am. J. Pathol., July 1, 2006; 169(1): 233 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Quackenbush Microarray analysis and tumor classification. N. Engl. J. Med., June 8, 2006; 354(23): 2463 - 2472. [Full Text] [PDF]
|
|
|
|
|
|
Z. Mi, H. Guo, P. Y. Wai, C. Gao, and P. C. Kuo Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells Carcinogenesis, June 1, 2006; 27(6): 1134 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. H.C. Bramwell, G. S. Doig, A. B. Tuck, S. M. Wilson, K. S. Tonkin, A. Tomiak, F. Perera, T. A. Vandenberg, and A. F. Chambers Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin. Cancer Res., June 1, 2006; 12(11): 3337 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Jang, T. Savarese, H. P. Low, S. Kim, H. Vogel, D. Lapointe, T. Duong, N. S. Litofsky, J. M. Weimann, A. H. Ross, et al. Osteopontin Expression in Intratumoral Astrocytes Marks Tumor Progression in Gliomas Induced by Prenatal Exposure to N-Ethyl-N-Nitrosourea Am. J. Pathol., May 1, 2006; 168(5): 1676 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bosco, K. L. McKenna, C. J. Devitt, M. J. Firth, P. D. Sly, and P. G. Holt Identification of novel th2-associated genes in T memory responses to allergens. J. Immunol., April 15, 2006; 176(8): 4766 - 4777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-T. Le, E. Chen, A. Salim, H. Cao, C. S. Kong, R. Whyte, J. Donington, W. Cannon, H. Wakelee, R. Tibshirani, et al. An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non-Small Cell Lung Cancers Clin. Cancer Res., March 1, 2006; 12(5): 1507 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. de Silva Rudland, L. Martin, C. Roshanlall, J. Winstanley, S. Leinster, A. Platt-Higgins, J. Carroll, C. West, R. Barraclough, and P. Rudland Association of S100A4 and Osteopontin with Specific Prognostic Factors and Survival of Patients with Minimally Invasive Breast Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1192 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ito, Y. Hashimoto, E. Tanaka, T. Kan, S. Tsunoda, F. Sato, M. Higashiyama, T. Okumura, and Y. Shimada An Inducible Short-Hairpin RNA Vector against Osteopontin Reduces Metastatic Potential of Human Esophageal Squamous Cell Carcinoma In vitro and In vivo Clin. Cancer Res., February 15, 2006; 12(4): 1308 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Khodavirdi, Z. Song, S. Yang, C. Zhong, S. Wang, H. Wu, C. Pritchard, P. S. Nelson, and P. Roy-Burman Increased Expression of Osteopontin Contributes to the Progression of Prostate Cancer Cancer Res., January 15, 2006; 66(2): 883 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-D. Zhang and T. W. Gant Effect of pooling samples on the efficiency of comparative studies using microarrays Bioinformatics, December 15, 2005; 21(24): 4378 - 4383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Celetti, D. Testa, S. Staibano, F. Merolla, V. Guarino, M. D. Castellone, R. Iovine, G. Mansueto, P. Somma, G. De Rosa, et al. Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness Clin. Cancer Res., November 15, 2005; 11(22): 8019 - 8027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Donati, L. Boldrini, M. Dell'Omodarme, M. C. Prati, P. Faviana, T. Camacci, M. Lucchi, A. Mussi, M. Santoro, F. Basolo, et al. Osteopontin Expression and Prognostic Significance in Non-Small Cell Lung Cancer Clin. Cancer Res., September 15, 2005; 11(18): 6459 - 6465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Gharib, D. L. Luchtel, D. K. Madtes, and R. W. Glenny Global gene annotation analysis and transcriptional profiling identify key biological modules in hypoxic pulmonary hypertension Physiol Genomics, June 16, 2005; 22(1): 14 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Eschrich, I. Yang, G. Bloom, K. Y. Kwong, D. Boulware, A. Cantor, D. Coppola, M. Kruhoffer, L. Aaltonen, T. F. Orntoft, et al. Molecular Staging for Survival Prediction of Colorectal Cancer Patients J. Clin. Oncol., May 20, 2005; 23(15): 3526 - 3535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Wai, Z. Mi, H. Guo, S. Sarraf-Yazdi, C. Gao, J. Wei, C. E. Marroquin, B. Clary, and P. C. Kuo Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis Carcinogenesis, April 1, 2005; 26(4): 741 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Helm, S. A. Enkemann, D. Coppola, J. S. Barthel, S. T. Kelley, and T. J. Yeatman Dedifferentiation Precedes Invasion in the Progression from Barrett's Metaplasia to Esophageal Adenocarcinoma Clin. Cancer Res., April 1, 2005; 11(7): 2478 - 2485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kendziorski, R. A. Irizarry, K.-S. Chen, J. D. Haag, and M. N. Gould On the utility of pooling biological samples in microarray experiments PNAS, March 22, 2005; 102(12): 4252 - 4257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. O'Connell, M. A. Maggard, and C. Y. Ko RESPONSE: Re: Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging J Natl Cancer Inst, March 16, 2005; 97(6): 464 - 464. [Full Text] [PDF]
|
|
|
|
|
|
H. Sultmann, A. v. Heydebreck, W. Huber, R. Kuner, A. Buness, M. Vogt, B. Gunawan, M. Vingron, L. Fuzesi, and A. Poustka Gene Expression in Kidney Cancer Is Associated with Cytogenetic Abnormalities, Metastasis Formation, and Patient Survival Clin. Cancer Res., January 15, 2005; 11(2): 646 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. W. Fisher, A. Jain, M. Tayback, and N. S. Fedarko Small Integrin Binding Ligand N-Linked Glycoprotein Gene Family Expression in Different Cancers Clin. Cancer Res., December 15, 2004; 10(24): 8501 - 8511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Mi, H. Guo, P. Y. Wai, C. Gao, J. Wei, and P. C. Kuo Differential Osteopontin Expression in Phenotypically Distinct Subclones of Murine Breast Cancer Cells Mediates Metastatic Behavior J. Biol. Chem., November 5, 2004; 279(45): 46659 - 46667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Schorge, R. D. Drake, H. Lee, S. J. Skates, R. Rajanbabu, D. S. Miller, J.-H. Kim, D. W. Cramer, R. S. Berkowitz, and S. C. Mok Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3474 - 3478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. El-Tanani, A. Platt-Higgins, P. S. Rudland, and F. C. Campbell Ets Gene PEA3 Cooperates with {beta}-Catenin-Lef-1 and c-Jun in Regulation of Osteopontin Transcription J. Biol. Chem., May 14, 2004; 279(20): 20794 - 20806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bloomston, A. Durkin, I. Yang, M. Rojiani, A. S. Rosemurgy, S. Enkmann, T. J. Yeatman, and E. E. Zervos Identification of Molecular Markers Specific for Pancreatic Neuroendocrine Tumors by Genetic Profiling of Core Biopsies Ann. Surg. Oncol., April 1, 2004; 11(4): 413 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, N. S. Fedarko, A. Jain, A. Maitra, C. Iacobuzio-Donahue, A. Rahman, R. H. Hruban, C. J. Yeo, and M. Goggins Evaluation of Osteopontin as Biomarker for Pancreatic Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 487 - 491. [Abstract] [Full Text]
|
|
|
|
|
|
S. Schneider, J. Yochim, J. Brabender, K. Uchida, K. D. Danenberg, R. Metzger, P. M. Schneider, D. Salonga, A. H. Holscher, and P. V. Danenberg Osteopontin But Not Osteonectin Messenger RNA Expression Is a Prognostic Marker in Curatively Resected Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2004; 10(5): 1588 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Coppola, M. Szabo, D. Boulware, P. Muraca, M. Alsarraj, A. F. Chambers, and T. J. Yeatman Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies Clin. Cancer Res., January 1, 2004; 10(1): 184 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gao, H. Guo, L. Downey, C. Marroquin, J. Wei, and P. C. Kuo Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells Carcinogenesis, December 1, 2003; 24(12): 1871 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-L. Chang, M. Cao, and P. Hicks Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells Carcinogenesis, November 1, 2003; 24(11): 1749 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Furger, A. L. Allan, S. M. Wilson, C. Hota, S. A. Vantyghem, C. O. Postenka, W. Al-Katib, A. F. Chambers, and A. B. Tuck {beta}3 Integrin Expression Increases Breast Carcinoma Cell Responsiveness to the Malignancy-Enhancing Effects of Osteopontin Mol. Cancer Res., September 1, 2003; 1(11): 810 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chen, I. Yang, R. Irby, K. H. Shain, H. G. Wang, J. Quackenbush, D. Coppola, J. Q. Cheng, and T. J. Yeatman Regulation of Caspase Expression and Apoptosis by Adenomatous Polyposis Coli Cancer Res., August 1, 2003; 63(15): 4368 - 4374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Tschentscher, J. Husing, T. Holter, E. Kruse, I. G. Dresen, K.-H. Jockel, G. Anastassiou, H. Schilling, N. Bornfeld, B. Horsthemke, et al. Tumor Classification Based on Gene Expression Profiling Shows That Uveal Melanomas with and without Monosomy 3 Represent Two Distinct Entities Cancer Res., May 15, 2003; 63(10): 2578 - 2584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Yeatman The Future of Cancer Management: Translating the Genome, Transcriptome, and Proteome Ann. Surg. Oncol., January 1, 2003; 10(1): 7 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.M. Svrakic, O. Nesic, M.R.K. Dasu, D. Herndon, and J.R. Perez-Polo Statistical Approach to DNA Chip Analysis Recent Prog. Horm. Res., January 1, 2003; 58(1): 75 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Denhardt Commentary re: Q-T. Le et al., Identification of Osteopontin as a Prognostic Marker for Head and Neck Squamous Cell Carcinomas. Clin. Cancer Res., 9: 31-32, 2003. Clin. Cancer Res., January 1, 2003; 9(1): 31 - 32. [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Weber Meeting Report: The Next Interleukin? Sci. Signal., August 27, 2002; 2002 (147): pe37 - pe37. [Abstract] [Full Text] [PDF]
|
|